Back to results

Old Dominion University

Type II Estrogen Binding-Site Agonist: The Synthesis and Biological Evaluation of the Enantiomers of Methyl-Para-Hydroxyphenyllactate (MeHPLA)

Abstract

dc:description.abstract

<p>The function of the type II estrogen binding site (EBS) has yet to be determined. However, a high affinity ligand for the binding site has been identified through HPLC and GC-MS. This ligand, MeHPLA, bears a structural relationship to a group of compounds called "phytoestrogens" which, along with MeHPLA, have been observed to suppress the cellular proliferation of estrogen sensitive MCF-7 breast cancer cells in vitro. Additionally, MeHPLA has been observed to suppress the growth of rat uteri in vivo. The high affinity of MeHPLA for the type II EBS suggests that this interaction is responsible for the observed suppression of cell growth. If this interaction is the mode of cell growth suppression, then the chiral center of MeHPLA might be expected to change the binding affinity of the ligand and the associated cellular activity. In this study, the enantiomers of MeHPLA were synthesized and separated by three methods. The methods included the use of the enantioselective catalyst, oxazoborolidine, the enzyme, lactate dehydrogenase, and the diastereomeric separation using a chiral amine. When the methods were compared, it was found that the method using the diastereomeric separation gave the superior yield for the two enantiomers. Binding studies for the enantiomers to the type II EBS showed that the L-MeHPLA isomer has a higher affinity for the binding site. However, binding affinity did not translate into cell growth suppression. Both enantiomers had the equivalent ability to suppress cellular growth. The conclusion is that the interaction of MeHPLA with the type II binding site may not be the mode by which cell growth suppression is achieved. This was supported by the evaluation of MeHPLA against LnCap prostate cancer cells and HxGC3 colon cancer cells in culture. Type II binding sites have been observed in prostate and colon cancer cell lines. However, their existence in these particular cell lines have not been confirmed. Some cellular growth suppression was observed in these cell lines upon treatment with MeHPLA. The possible function of MeHPLA was also compared to other phytoestrogens that appear to act independently of the type II EBS. Their activity was compared to a group of compounds known as xenoestrogens. MeHPLA, phytoestrogens, and xenoestrogens have the ability to stimulate, inhibit, or compromise normal or malignant cells with in the reproductive tract.</p>

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy (PhD)
Level thesis:degree_level
Dissertation
Year dc:date.available
1997

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Pretlow, Lester G.
Contributors dc:contributor
  • Roy L. Wiliams
  • Mark S. Elliot
  • Patricia A. Pleban
  • Paul Ratz

Subjects

dc:subject × 5

Identifiers

dc:identifier.*
Identifier
9780591603934
OAI identifier oai:identifier
oai:digitalcommons.odu.edu:biomedicalsciences_etds-1070

Chain of custody

source
Harvested from
Old Dominion University
Base URL
digitalcommons.odu.edu/do/oai/
Last updated
2026-07-24
Source record
OAI-PMH GetRecord
citation

Pretlow, Lester G.. Type II Estrogen Binding-Site Agonist: The Synthesis and Biological Evaluation of the Enantiomers of Methyl-Para-Hydroxyphenyllactate (MeHPLA). Dissertation thesis, 1997. https://digitalcommons.odu.edu/biomedicalsciences_etds/70